AAO 2024: EyePoint’s EYP-1901 proves non-inferiority to aflibercept in DAVIO 2
Pharmaceutical Technology
OCTOBER 20, 2024
While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.
Pharmaceutical Technology
OCTOBER 20, 2024
While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.
FDA Law Blog
OCTOBER 20, 2024
By Larry K. Houck — Eric Idle, as a body collector, immortalized the phrase, “Bring out your dead! Bring out your dead!” in the 1975 comedy classic, Monty Python and the Holy Grail. The Drug Enforcement Administration (“DEA”) would do well to update that phrase as “Bring out your meds! Bring out your meds!” to call attention to the 26th National Prescription Take Back Day.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 20, 2024
At its second attempt, Astellas won FDA approval for its first-in-class cancer therapy, Vyloy, which got the green light for claudin 18.
JAMA Internal Medicine
OCTOBER 20, 2024
This randomized clinical trial evaluates the effect of a patient/caregiver and prescriber-mailed educational intervention on potentially inappropriate prescribing to patients with Alzheimer disease or Alzheimer disease–related dementias.
Speaker: Simran Kaur, Founder & CEO at Tattva Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Let's personalize your content